0.07
+1.56%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Uni-Bio Science Group
Its shares trade on HKEX under the ticker 690.HK. It has been listed since 12 November 2001. In the fiscal year to 31 December 2024, it reported revenue of HK$553.0m and net income of HK$82.8m. At that date it held total assets of HK$517.6m and shareholders' equity of HK$325.6m.
Uni-Bio Science Group Ltd. is an investment holding company with interests in pharmaceutical research and development. The company employs 340 full-time employees The company went IPO on 2001-11-12. The firm operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Nov 2001
- Employees
- 340
- Website
- uni-bioscience.com ↗
Leadership
Pay as last reported
- Mr. Leung KingsleyExecutive Chairman of the Board, since 2014HK$787,000
- Mr. Zhi Gang ZhaoChief Executive Officer, Executive Director, since 2014HK$1.6m
- Mr. Dawei ChenExecutive Vice Chairman of the Board, since 2017HK$1.4m
- Mr. Kai DuFinancial Controller
- Dr. Ya Lei WenExecutive Director
- Mr. Wen Du AnHead - Sales Department
- Ms. Jing LiHead - Research and Development
- Ms. Wei TianHead - Human Resource and Administration
- Mr. Huanan ZhaoHead - Medicine and Registration Department
- Ms. Wing Yan HoCompany Secretary
- Mr. Kwok Wing YauNon-Executive DirectorHK$200,000
- Ms. Qing ZhangNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company has 340 full-time employees.
- It operates through four distinct business segments.
- It manufactures in-house chemical and biological products.
Weaknesses
- The city of operation is unknown.
- The source description is treated as untrusted.
- Specific financial data is not provided.
Opportunities
- It can industrialize its biological pipeline products.
- It sells third-party pharmaceutical products.
- It markets products like Pinapu and GeneTime.
Threats
- The IPO occurred in 2001, which is long ago.
- The ISIN is KYG9198H1406.
- The ticker is 690.HK on the HK exchange.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.